Plain-English translation of NCT03667417 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a long-term observational study that follows people who carry a BRCA1 or BRCA2 gene mutation—mutations that significantly increase the risk of developing breast and ovarian cancer. Researchers want to understand how this genetic predisposition affects cancer development in real life, whether or not participants have been diagnosed with cancer already. By tracking participants over time, they hope to gain insights that could improve screening, prevention, and treatment strategies for people with these genetic mutations.
People with BRCA mutations face a much higher lifetime risk of breast and ovarian cancer, but doctors don't yet have complete information about how this risk develops over time and what factors influence it. This study aims to fill that gap by carefully following a large group of mutation carriers, which could help doctors better predict who will develop cancer and when, and ultimately improve care for this high-risk population.
You likely qualify if…
You likely don't qualify if…
As a participant, you would join a long-term registry where your health information is tracked over time. This involves regular clinic visits where researchers will monitor your health history, any cancer diagnoses, and relevant medical information. The study is designed to follow participants for an extended period, so you would be expected to check in periodically with the research team and share updates about your health status.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
France
Sponsor
Institut Paoli-Calmettes
Collaborators
UNICANCER - Le Groupe génétique et cancer (GGC)
Enrollment target
~5,000 participants
Started
October 1999
Primary completion
October 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2020.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dominique GENRE, MD
Institut Paoli-Calmettes
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.